Dyadic International Inc (DYAI) - Net Assets

Latest as of September 2025: $2.61 Million USD

Based on the latest financial reports, Dyadic International Inc (DYAI) has net assets worth $2.61 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.67 Million) and total liabilities ($9.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Dyadic International Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets $2.61 Million
% of Total Assets 22.34%
Annual Growth Rate N/A
5-Year Change -91.32%
10-Year Change -96.65%
Growth Volatility 111.58

Dyadic International Inc - Net Assets Trend (2003–2024)

This chart illustrates how Dyadic International Inc's net assets have evolved over time, based on quarterly financial data. Also explore DYAI asset base for the complete picture of this company's asset base.

Annual Net Assets for Dyadic International Inc (2003–2024)

The table below shows the annual net assets of Dyadic International Inc from 2003 to 2024. For live valuation and market cap data, see market cap of Dyadic International Inc.

Year Net Assets Change
2024-12-31 $2.47 Million -57.98%
2023-12-31 $5.88 Million -46.98%
2022-12-31 $11.09 Million -39.71%
2021-12-31 $18.39 Million -35.35%
2020-12-31 $28.45 Million -20.68%
2019-12-31 $35.86 Million -15.52%
2018-12-31 $42.45 Million -15.06%
2017-12-31 $49.98 Million -13.37%
2016-12-31 $57.69 Million -21.82%
2015-12-31 $73.79 Million +3358.38%
2014-12-31 $-2.26 Million -188.18%
2013-12-31 $2.57 Million +43.71%
2012-12-31 $1.79 Million +323.39%
2011-12-31 $-800.00K -132.79%
2010-12-31 $2.44 Million -64.94%
2009-12-31 $6.96 Million +376.71%
2008-12-31 $1.46 Million -89.19%
2007-12-31 $13.50 Million -52.11%
2006-12-31 $28.19 Million +83.33%
2005-12-31 $15.38 Million -37.41%
2004-12-31 $24.57 Million +33260.81%
2003-12-31 $-74.09K --

Equity Component Analysis

This analysis shows how different components contribute to Dyadic International Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 8587121600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $42.09K 1.70%
Other Components $88.51 Million 3583.17%
Total Equity $2.47 Million 100.00%

Dyadic International Inc Competitors by Market Cap

The table below lists competitors of Dyadic International Inc ranked by their market capitalization.

Company Market Cap
Workhorse Group Inc
NASDAQ:WKHS
$28.60 Million
DIAMINES AND CHEMICALS ORD (BSE)
NSE:DIAMINESQ
$28.60 Million
GFM Services Bhd
KLSE:0039
$28.60 Million
SHH Resources Holdings Bhd
KLSE:7412
$28.62 Million
Ekso Bionics Holdings Inc
NASDAQ:EKSO
$28.58 Million
GLORY HEALTH IND. HD-001
F:84R
$28.58 Million
Prestar Resources Bhd
KLSE:9873
$28.57 Million
SFD SA ZY -10
F:7PQ
$28.55 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Dyadic International Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 5,878,585 to 2,470,290, a change of -3,408,295 (-58.0%).
  • Net loss of 5,809,159 reduced equity.
  • Other factors increased equity by 2,400,864.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-5.81 Million -235.16%
Other Changes $2.40 Million +97.19%
Total Change $- -57.98%

Book Value vs Market Value Analysis

This analysis compares Dyadic International Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 9.38x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2003-12-31 $-0.01 $0.79 x
2004-12-31 $1.50 $0.79 x
2005-12-31 $0.69 $0.79 x
2006-12-31 $1.15 $0.79 x
2007-12-31 $0.45 $0.79 x
2008-12-31 $0.05 $0.79 x
2009-12-31 $0.21 $0.79 x
2010-12-31 $0.08 $0.79 x
2012-12-31 $0.05 $0.79 x
2013-12-31 $0.08 $0.79 x
2014-12-31 $-0.07 $0.79 x
2015-12-31 $2.15 $0.79 x
2016-12-31 $1.58 $0.79 x
2017-12-31 $1.73 $0.79 x
2018-12-31 $1.53 $0.79 x
2019-12-31 $1.33 $0.79 x
2020-12-31 $1.04 $0.79 x
2021-12-31 $0.66 $0.79 x
2022-12-31 $0.39 $0.79 x
2023-12-31 $0.20 $0.79 x
2024-12-31 $0.08 $0.79 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Dyadic International Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -235.16%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -166.19%
  • • Asset Turnover: 0.35x
  • • Equity Multiplier: 4.02x
  • Recent ROE (-235.16%) is below the historical average (-27.70%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2003 0.00% -90.30% 12.82x 0.00x $-183.37K
2004 -24.85% -36.32% 0.51x 1.34x $-8.53 Million
2005 -68.85% -66.20% 0.67x 1.56x $-12.04 Million
2006 -38.60% -70.74% 0.34x 1.60x $-13.70 Million
2009 75.30% 24.47% 1.49x 2.06x $4.54 Million
2012 75.51% 8.65% 1.21x 7.21x $1.17 Million
2013 -16.67% -2.50% 1.15x 5.82x $-684.87K
2014 0.00% -47.75% 1.47x 0.00x $-5.75 Million
2015 89.15% 20837.76% 0.00x 1.04x $58.41 Million
2016 -6.26% -608.67% 0.01x 1.02x $-9.38 Million
2017 -4.27% -281.61% 0.01x 1.02x $-7.13 Million
2018 -13.41% -439.36% 0.03x 1.02x $-9.94 Million
2019 -23.16% -494.21% 0.04x 1.04x $-11.89 Million
2020 -32.78% -582.13% 0.05x 1.06x $-12.17 Million
2021 -71.07% -543.73% 0.11x 1.16x $-14.91 Million
2022 -87.80% -332.23% 0.21x 1.24x $-10.84 Million
2023 -115.60% -234.42% 0.35x 1.40x $-7.38 Million
2024 -235.16% -166.19% 0.35x 4.02x $-6.06 Million

Industry Comparison

This section compares Dyadic International Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $44,828,400
  • Average return on equity (ROE) among peers: -124.18%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Dyadic International Inc (DYAI) $2.61 Million 0.00% 3.48x $28.59 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-54.64 Million 0.00% 0.00x $118.88 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $1.07 Billion
Abeona Therapeutics Inc (ABEO) $3.60 Million -91.89% 0.28x $292.09 Million
Acumen Pharmaceuticals Inc (ABOS) $266.97 Million -19.62% 0.16x $171.87 Million
Abpro Holdings, Inc. (ABP) $3.07 Million -479.81% 1.57x $448.19K
Absci Corp (ABSI) $67.00 Million -21.42% 0.32x $345.85 Million
Arbutus Biopharma Corp (ABUS) $88.00 Million -44.09% 0.34x $840.56 Million
ABVC Biopharma Inc (ABVC) $80.00K -31.70% 0.38x $26.41 Million
Abivax SA American Depositary Shares (ABVX) $40.58 Million -434.26% 4.06x $9.33 Billion
ACADIA Pharmaceuticals Inc (ACAD) $23.36 Million -97.44% 0.37x $3.74 Billion

About Dyadic International Inc

NASDAQ:DYAI USA Biotechnology
Market Cap
$28.59 Million
Market Cap Rank
#23852 Global
#4917 in USA
Share Price
$0.79
Change (1 day)
+0.70%
52-Week Range
$0.68 - $1.30
All Time High
$10.26
About

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and la… Read more